NEW YORK, December 17, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting MiMedx Group, Inc. (NASDAQ: MDXG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), VIVUS Inc. (NASDAQ: VVUS), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), and GenVec, Inc. (NASDAQ: GNVC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
MiMedx Group, Inc. Research Report
On December 12, 2013, MiMedx Group, Inc. (MiMedx) announced the pricing of an underwritten public offering of 5 million shares of its common stock at a price to the public of $6.80 per share for gross proceeds of $34.0 million. According to the Company, the net proceeds from the sale of the shares, after deductions, will be approximately $31.6 million. Additionally, MiMedx informed that it has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock tocover any over-allotments. MiMedx stated that offering's proceeds will be used for general corporate purposes including research, development and further commercialization of the Company's products, obtaining regulatory approvals, funding of clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products. MiMedx also stated that the offering is expected to close on or about December 17, 2013, subject to customary closing conditions. The Full Research Report on MiMedx Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
NPS Pharmaceuticals, Inc. Research Report
On December 12, 2013, NPS Pharmaceuticals, Inc.'s (NPS Pharmaceuticals) stock went up by 6.45%, closing the day at $24.10. For the past three trading days, NPS Pharmaceuticals' stock went up by 0.88%, compared to the Dow Jones Industrial Average which went down by 1.79% during the same three day trading period. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
VIVUS Inc. Research Report
On December 12, 2013, VIVUS Inc. (VIVUS) announced that it has entered into a License and Commercialization Agreement with Sanofi for commercializing avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia. VIVUS stated that Sanofi will be responsible for obtaining regulatory approval in its territories, and plans to market avanafil under the tradename SPEDRA™ or STENDRA™. The Company stated that under the terms of the agreement,itis eligible to receive up to $61 million in upfront payments, regulatory and sales milestones, and escalating royalties based on net sales over the life of the agreement. Commenting on the release, John L. Slebir, Vice President, Business Development and General Counsel of VIVUS, stated, "We are pleased with the alliance we have forged with our partners at Sanofi. This agreement is another key accomplishment for VIVUS in the monetization of avanafil."The Full Research Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Merrimack Pharmaceuticals, Inc. Research Report
On December 12, 2013, Merrimack Pharmaceuticals, Inc.'s (Merrimack Pharmaceuticals) stock went up by 12.10%, to close the day at $4.54. The Company's stock went up by 1.57% over the past three trading days, compared to the Dow Jones Industrial Average which went down by 1.79% during the same trading period. The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
GenVec, Inc. Research Report
On December 12, 2013, GenVec, Inc.'s (GenVec) stock climbed up 31.03% to close the day at $2.28. Over the past three trading days, the Company's stock went up by 23.91%, compared to the Nasdaq Composite which went down by 1.73% during the same trading period. The Full Research Report on GenVec, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner